- Always ≥ 99% purity
- Manufactured and sealed in a sterile environment
- Up to 70% more value in each bottle
- Each batch is independently double-tested
LGD-3303 is a nonsteroidal Selective Androgen Receptor Modulator (SARM) under investigation in preclinical research for its tissue-selective anabolic properties. In comparative studies, LGD-3303 has demonstrated potent androgen receptor agonism in skeletal muscle and partial agonist activity in other androgen-responsive tissues, contributing to its favorable selectivity profile.
This compound was developed to address certain limitations observed in earlier generation SARMs, such as LGD-4033, with particular improvements in oral bioavailability and bone-anabolic activity. In vivo studies have shown that LGD-3303 supports the preservation of lean body mass and enhances skeletal parameters, including bone mineral density and biomechanical strength, with minimal androgenic stimulation in non-target tissues.

In preclinical studies, LGD-3303 has demonstrated the ability to:
Ongoing research involving LGD-3303 includes its use in experimental models of musculoskeletal degeneration, androgen deficiency, and age-associated sarcopenia and osteopenia. Its pharmacological profile makes it a candidate of interest for investigating selective androgen receptor modulation mechanisms without the off-target effects typically associated with classical anabolic agents.
⚠ Important Note: This product is supplied strictly for laboratory research use only. It is not approved for human consumption or therapeutic use. Not intended to diagnose, treat, cure, or prevent any disease.
| Delivery - UK | Next working day |
|---|---|
| Delivery - Worldwide | 5-7 working days + customs processing time (varies) |
| Stock levels | Low |
| CAS Number | 917891-35-1 |
| Molecular formula | C16H14ClF3N2O |
| Molar mass | 342.75 g/mol |
| Purity | ≥99% (see HPLC and COA documentation) |
| Concentration | 10 mg |
| Half-life | ~6-12 hours |
| Storage | 2 years at 20°C |
There are no reviews yet.